Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.63 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306682 | 0.89 | NOS2 (0.62) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 | |
| SCHEMBL4312492 | 0.89 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 | |
| SCHEMBL4305445 | 0.89 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3NOS2CACNA1B | |
| SCHEMBL4305010 | 0.87 | NOS2 (0.62) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 | |
| SCHEMBL4306762 | 0.87 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 | |
| SCHEMBL4682986 | 0.87 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3NOS2CACNA1B | |
| SCHEMBL4684474 | 0.85 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3NOS2CACNA1B | |
| SCHEMBL4315201 | 0.84 | SLC6A4 (0.61) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 | |
| SCHEMBL27815200 | 0.83 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3NOS2CACNA1B | |
| SCHEMBL4311464 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3NOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101977904-A | Aminopiperidinyl derivatives and uses thereof | HOFFMANN LA ROCHE | 2011-02-16 | — | — | CN | disclosed |
| EP-1551827-B1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009118254-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-7488741-B2 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB PHARMA, S.A. (BE) | 2009-02-10 | — | — | US | disclosed |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | NOVARTIS AG | 2008-10-09 | — | — | US | disclosed |
| US-7399771-B2 | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| CN-100334083-C | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2007-08-29 | — | — | CN | disclosed |
| EP-1693061-A1 | Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases | UCB, S.A. (BE) | 2006-08-23 | — | — | EP | disclosed |
| EP-1556045-B1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB SA (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB, S.A. (BE) | 2006-06-15 | — | — | US | disclosed |
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | NOVARTIS AG (CH) | 2006-01-05 | — | — | US | disclosed |
| CN-1703411-A | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2005-11-30 | — | — | CN | disclosed |
| CN-1688307-A | 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments | UCB SA (BE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1556045-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1551827-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004030668-A1 | 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB, S.A. (BE) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031172-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | CCR5, CCR2, CCR1 | SLC6A2 1436/4885SLC6A4 873/4885SLC6A3 628/4885 |
| US-20060128753-A1 | 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments | PNMT, HTR5A, HTR4 | SLC6A2 112/4885SLC6A4 50/4885SLC6A3 354/4885 |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | CCR5, CCR2, CCR1 | SLC6A2 899/4885SLC6A4 659/4885SLC6A3 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.